{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:07:19Z","timestamp":1790662039437,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00467-023-05974-2","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T02:01:27Z","timestamp":1683338487000},"page":"85-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review"],"prefix":"10.1007","volume":"39","author":[{"given":"Fiona Fung-yee","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-6005","authenticated-orcid":false,"given":"Eugene Yu-hin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"Tullus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison Lap-tak","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"5974_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.ajkd.2022.05.013","volume":"81","author":"M Marlais","year":"2022","unstructured":"Marlais M, Wlodkowski T, Printza N, Kronsteiner D, Krisam R, Sauer L, Aksenova M, Ashoor I, Awan A, Bacchetta J (2022) Clinical factors and adverse kidney outcomes in children with antineutrophil cytoplasmic antibody\u2013associated glomerulonephritis. Am J Kidney Dis 81:119\u2013122. https:\/\/doi.org\/10.1053\/j.ajkd.2022.05.013","journal-title":"Am J Kidney Dis"},{"key":"5974_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00467-021-05405-0","volume":"37","author":"MH Lee","year":"2022","unstructured":"Lee MH, Chan EY, Ma AL (2022) Timely and individualized use of immunosuppression is associated with favourable outcomes in paediatric IgA vasculitis nephritis. Pediatr Nephrol 37:913\u2013914. https:\/\/doi.org\/10.1007\/s00467-021-05405-0","journal-title":"Pediatr Nephrol"},{"key":"5974_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ekir.2022.10.014","volume":"8","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yap DY, Wong W, Wong WH, Wong S, Lin KY, Hui FY, Li JY, Lam SS, Wong JK (2022) Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis. Kidney Int Rep 8:141\u2013150. https:\/\/doi.org\/10.1016\/j.ekir.2022.10.014","journal-title":"Kidney Int Rep"},{"key":"5974_CR4","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Ellen L, Angeletti A, Arslan Z, Basu B, Boyer O, Chan C-Y, Colucci M, Dorval G, Dossier C (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"key":"5974_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/nep.14007","volume":"27","author":"EYH Chan","year":"2022","unstructured":"Chan EYH, Yap DYH, Wong WHS, Ho TW, Tong PC, Lai WM, Chan TM, Ma ALT (2022) Demographics and long-term outcomes of children with end-stage kidney disease: a 20-year territory-wide study. Nephrology (Carlton) 27:171\u2013180. https:\/\/doi.org\/10.1111\/nep.14007","journal-title":"Nephrology (Carlton)"},{"key":"5974_CR6","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00467-020-04788-w","volume":"36","author":"EY Chan","year":"2021","unstructured":"Chan EY, Ma AL, Tullus K (2021) When should we start and stop ACEi\/ARB in paediatric chronic kidney disease? Pediatr Nephrol 36:1751\u20131764. https:\/\/doi.org\/10.1007\/s00467-020-04788-w","journal-title":"Pediatr Nephrol"},{"key":"5974_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ (2021) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100:753\u2013779","journal-title":"Kidney Int"},{"key":"5974_CR8","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1007\/s00467-021-05135-3","volume":"36","author":"R Ehren","year":"2021","unstructured":"Ehren R, Benz MR, Brinkk\u00f6tter PT, D\u00f6tsch J, Eberl WR, Gellermann J, Hoyer PF, Jordans I, Kamrath C, Kemper MJ (2021) Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy\u2014short version of the updated German best practice guideline (S2e)\u2014AWMF register no. 166\u2013001, 6\/2020. Pediatr Nephrol 36:2971\u20132985","journal-title":"Pediatr Nephrol"},{"key":"5974_CR9","doi-asserted-by":"publisher","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, International Pediatric Nephrology Association (2022) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3","DOI":"10.1007\/s00467-022-05739-3"},{"key":"5974_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13312-021-2217-3","volume":"58","author":"A Sinha","year":"2021","unstructured":"Sinha A, Bagga A, Banerjee S, Mishra K, Mehta A, Agarwal I, Uthup S, Saha A, Mishra OP, Expert Group of Indian Society of Pediatric Nephrology (2021) Steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 58:461\u2013481","journal-title":"Indian Pediatr"},{"key":"5974_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00467-021-04983-3","volume":"37","author":"F Zotta","year":"2022","unstructured":"Zotta F, Vivarelli M, Emma F (2022) Update on the treatment of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 37:303\u2013314","journal-title":"Pediatr Nephrol"},{"key":"5974_CR12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529\u20131561","journal-title":"Pediatr Nephrol"},{"key":"5974_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s13312-021-2262-y","volume":"58","author":"A Vasudevan","year":"2021","unstructured":"Vasudevan A, Thergaonkar R, Mantan M, Sharma J, Khandelwal P, Hari P, Sinha A, Bagga A, Expert Group of Indian Society of Pediatric Nephrology (2021) Consensus guidelines on management of steroid-resistant nephrotic syndrome. Indian Pediatr 58:650\u2013666","journal-title":"Indian Pediatr"},{"key":"5974_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/00003088-199528050-00005","volume":"28","author":"B Vrhovac","year":"1995","unstructured":"Vrhovac B, Sarapa N, Bakran I, Huic M, Macolic-Sarinic V, Francetic I, Wolf-Coporda A, Plavsic F (1995) Pharmacokinetic changes in patients with oedema. Clin Pharmacokinet 28:405\u2013418","journal-title":"Clin Pharmacokinet"},{"key":"5974_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s00467-006-0300-6","volume":"22","author":"M Medeiros","year":"2007","unstructured":"Medeiros M, P\u00e9rez-Urizar J, Mej\u00eda-Gaviria N, Ram\u00edrez-L\u00f3pez E, Casta\u00f1eda-Hern\u00e1ndez G, Mu\u00f1oz R (2007) Decreased cyclosporine exposure during the remission of nephrotic syndrome. Pediatr Nephrol 22:84\u201390","journal-title":"Pediatr Nephrol"},{"key":"5974_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5414\/CN109583","volume":"91","author":"A Kirpalani","year":"2019","unstructured":"Kirpalani A, Rothfels L, Sharma AP, Cuellar CR, Filler G (2019) Nephrotic state substantially enhances apparent mycophenolic acid clearance. Clin Nephrol 91:162","journal-title":"Clin Nephrol"},{"key":"5974_CR17","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/1440-1681.13706","volume":"49","author":"J Sobiak","year":"2022","unstructured":"Sobiak J, Resztak M, Zachwieja J, Ostalska-Nowicka D (2022) Inosine monophosphate dehydrogenase activity and mycophenolate pharmacokinetics in children with nephrotic syndrome treated with mycophenolate mofetil. Clin Exp Pharmacol Physiol 49:1197\u20131208","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"5974_CR18","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.3390\/molecules26123723","volume":"26","author":"J Sobiak","year":"2021","unstructured":"Sobiak J, Resztak M, Chrzanowska M, Zachwieja J, Ostalska-Nowicka D (2021) The evaluation of multiple linear regression\u2013based limited sampling strategies for mycophenolic acid in children with nephrotic syndrome. Molecules 26:3723","journal-title":"Molecules"},{"key":"5974_CR19","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00228-019-02701-5","volume":"75","author":"J Sobiak","year":"2019","unstructured":"Sobiak J, Resztak M, Pawi\u0144ski T, \u017bero P, Ostalska-Nowicka D, Zachwieja J, Chrzanowska M (2019) Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study. Eur J Clin Pharmacol 75:1249\u20131259","journal-title":"Eur J Clin Pharmacol"},{"key":"5974_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.clinbiochem.2015.10.001","volume":"49","author":"S Bergan","year":"2016","unstructured":"Bergan S, Bremer S, Vethe NT (2016) Drug target molecules to guide immunosuppression. Clin Biochem 49:411\u2013418","journal-title":"Clin Biochem"},{"key":"5974_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00467-014-2813-8","volume":"30","author":"LT Weber","year":"2015","unstructured":"Weber LT (2015) Therapeutic drug monitoring in pediatric renal transplantation. Pediatr Nephrol 30:253\u2013265","journal-title":"Pediatr Nephrol"},{"key":"5974_CR22","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1515\/CCLM.2004.242","volume":"42","author":"PE Wallemacq","year":"2004","unstructured":"Wallemacq PE (2004) Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med 42:1204\u20131211","journal-title":"Clin Chem Lab Med"},{"key":"5974_CR23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.clinbiochem.2010.06.007","volume":"43","author":"EM Brate","year":"2010","unstructured":"Brate EM, Finley DM, Grote J, Holets-McCormack S, Ozaeta PF, Pacenti D, Peart JE, Piktel RE, Ramsay CS, Rupprecht KR (2010) Development of an Abbott ARCHITECT cyclosporine immunoassay without metabolite cross-reactivity. Clin Biochem 43:1152\u20131157","journal-title":"Clin Biochem"},{"key":"5974_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/FTD.0000000000000696","volume":"42","author":"T Shigematsu","year":"2020","unstructured":"Shigematsu T, Suetsugu K, Yamamoto N, Tsuchiya Y, Masuda S (2020) Comparison of 4 commercial immunoassays used in measuring the concentration of tacrolimus in blood and their cross-reactivity to its metabolites. Ther Drug Monit 42:400\u2013406","journal-title":"Ther Drug Monit"},{"key":"5974_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/FTD.0b013e31811f25df","volume":"29","author":"IS Westley","year":"2007","unstructured":"Westley IS, Taylor PJ, Salm P, Morris RG (2007) Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients. Ther Drug Monit 29:584\u2013591","journal-title":"Ther Drug Monit"},{"key":"5974_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S (2021) Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit 43:150\u2013200","journal-title":"Ther Drug Monit"},{"key":"5974_CR27","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00467-015-3120-8","volume":"30","author":"CE Counsilman","year":"2015","unstructured":"Counsilman CE, Jol\u2013van der Zijde CM, Stevens J, Cransberg K, Bredius RG, Sukhai RN (2015) Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol 30:1367\u20131370","journal-title":"Pediatr Nephrol"},{"key":"5974_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, Van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 41:261\u2013307","journal-title":"Ther Drug Monit"},{"key":"5974_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1399-3046.2005.00263.x","volume":"9","author":"JS Kim","year":"2005","unstructured":"Kim JS, Aviles DH, Silverstein DM, LeBlanc PL, MattiVehaskari V (2005) Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 9:162\u2013169","journal-title":"Pediatr Transplant"},{"key":"5974_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00003088-199732060-00004","volume":"32","author":"GF Cooney","year":"1997","unstructured":"Cooney GF, Habucky K, Hoppu K (1997) Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 32:481\u2013495","journal-title":"Clin Pharmacokinet"},{"key":"5974_CR31","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2165\/00003495-200161130-00006","volume":"61","author":"J Christopher","year":"2001","unstructured":"Christopher J, Dunn J, Caroline M, Greg L, Karen L (2001) Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral\u00ae) l in organ transplantation. Drugs 61:1957\u20132016","journal-title":"Drugs"},{"key":"5974_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00467-018-4117-x","volume":"34","author":"AM Schijvens","year":"2019","unstructured":"Schijvens AM, van Hesteren FH, Cornelissen EA, Bootsma-Robroeks CM, Br\u00fcggemann RJ, Burger DM, de Wildt SN, Schreuder MF, Ter Heine R (2019) The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatr Nephrol 34:507\u2013515","journal-title":"Pediatr Nephrol"},{"key":"5974_CR33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321\u20131328","journal-title":"Pediatr Nephrol"},{"key":"5974_CR34","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.11791018","volume":"14","author":"B Seitz-Polski","year":"2019","unstructured":"Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G (2019) High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin J Am Soc Nephrol 14:1173\u20131182","journal-title":"Clin J Am Soc Nephrol"},{"key":"5974_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2215\/CJN.13071212","volume":"9","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Oba MS, Ito S, Hataya H, Tanaka R, Ohwada Y, Kamei K, Ishikura K, Yata N (2014) Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial. Clin J Am Soc Nephrol 9:271\u2013278","journal-title":"Clin J Am Soc Nephrol"},{"key":"5974_CR36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ki.2008.24","volume":"73","author":"K Ishikura","year":"2008","unstructured":"Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, Nakanishi K, Yata N, Honda M (2008) Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int 73:1167\u20131173","journal-title":"Kidney Int"},{"key":"5974_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2017.01.019","volume":"92","author":"A Sinha","year":"2017","unstructured":"Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A (2017) Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney Int 92:248\u2013257","journal-title":"Kidney Int"},{"key":"5974_CR38","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.2012.238","volume":"82","author":"A Gulati","year":"2012","unstructured":"Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, Mantan M, Agarwal I, Dinda AK, Hari P (2012) Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 82:1130\u20131135","journal-title":"Kidney Int"},{"key":"5974_CR39","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","volume":"53","author":"S Choudhry","year":"2009","unstructured":"Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A (2009) Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 53:760\u2013769","journal-title":"Am J Kidney Dis"},{"key":"5974_CR40","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1681\/ASN.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann J, Weber L, Pape L, T\u00f6nshoff B, Hoyer P, Querfeld U (2013) Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24:1689\u20131697","journal-title":"J Am Soc Nephrol"},{"key":"5974_CR41","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","volume":"23","author":"EM Dorresteijn","year":"2008","unstructured":"Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23:2013\u20132020","journal-title":"Pediatr Nephrol"},{"key":"5974_CR42","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s00467-022-05475-8","volume":"37","author":"G Mathew","year":"2022","unstructured":"Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P, Bagga A (2022) Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. Pediatr Nephrol 37:3117\u20133126","journal-title":"Pediatr Nephrol"},{"key":"5974_CR43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra T, Schaefer F (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172:757\u2013764","journal-title":"JAMA Pediatr"},{"key":"5974_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1681\/ASN.V32254","volume":"3","author":"E Ingulli","year":"1992","unstructured":"Ingulli E, Tejani A (1992) Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome. J Am Soc Nephrol 3:254\u2013259","journal-title":"J Am Soc Nephrol"},{"key":"5974_CR45","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1093\/ndt\/gfq318","volume":"25","author":"K Ishikura","year":"2010","unstructured":"Ishikura K, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Yata N, Ando T, Honda M (2010) Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transplant 25:3956\u20133962","journal-title":"Nephrol Dial Transplant"},{"key":"5974_CR46","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/ndt\/gfh803","volume":"20","author":"G Filler","year":"2005","unstructured":"Filler G (2005) How should microemulsified Cyclosporine A (Neoral\u00ae) therapy in patients with nephrotic syndrome be monitored? Nephrol Dial Transplant 20:1032\u20131034","journal-title":"Nephrol Dial Transplant"},{"key":"5974_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1034\/j.1399-3046.2002.02019.x","volume":"6","author":"E David-Neto","year":"2002","unstructured":"David-Neto E, Araujo LP, Feres Alves C, Sumita N, Romano P, Yagyu EM, Nahas WC, Ianhez LE (2002) A strategy to calculate cyclosporin A area under the time\u2013concentration curve in pediatric renal transplantation. Pediatr Transplant 6:313\u2013318","journal-title":"Pediatr Transplant"},{"key":"5974_CR48","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00467-005-1844-6","volume":"20","author":"K Nozu","year":"2005","unstructured":"Nozu K, Iijima K, Sakaeda T, Okumura K, Nakanishi K, Yoshikawa N, Honda M, Ikeda M, Matsuo M (2005) Cyclosporin A absorption profiles in children with nephrotic syndrome. Pediatr Nephrol 20:910\u2013913","journal-title":"Pediatr Nephrol"},{"key":"5974_CR49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s10157-021-02139-z","volume":"26","author":"T Nishino","year":"2022","unstructured":"Nishino T, Takahashi K, Tomori S, Ono S, Mimaki M (2022) Cyclosporine A C1. 5 monitoring reflects the area under the curve in children with nephrotic syndrome: a single-center experience. Clin Exp Nephrol 26:154\u2013161","journal-title":"Clin Exp Nephrol"},{"key":"5974_CR50","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00467-004-1802-8","volume":"20","author":"S Fanta","year":"2005","unstructured":"Fanta S, Backman JT, Seikku P, Holmberg C, Hoppu K (2005) Cyclosporine A monitoring\u2013how to account for twice and three times daily dosing. Pediatr Nephrol 20:591\u2013596","journal-title":"Pediatr Nephrol"},{"key":"5974_CR51","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1399-3046.2006.00592.x","volume":"10","author":"G Filler","year":"2006","unstructured":"Filler G, De Barros VR, Jagger JE, Christians U (2006) Cyclosporin twice or three times daily dosing in pediatric transplant patients\u2013it is not the same! Pediatr Transplant 10:953\u2013956","journal-title":"Pediatr Transplant"},{"key":"5974_CR52","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2215\/CJN.01520209","volume":"4","author":"S-W Kengne","year":"2009","unstructured":"Kengne S-W, Massella L, Diomedi F-C, Gianviti A, Vivarelli M, Greco M, Rita GS, Emma F (2009) Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol 4:1409\u20131416","journal-title":"Clin J Am Soc Nephrol"},{"key":"5974_CR53","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/FTD.0000000000000285","volume":"38","author":"M Medeiros","year":"2016","unstructured":"Medeiros M, Valverde S, Del Moral I, Vel\u00e1squez-Jones L, Hern\u00e1ndez AM, Casta\u00f1eda-Hern\u00e1ndez G, Reyes H, Filler G (2016) Are tacrolimus pharmacokinetics affected by nephrotic stage? Ther Drug Monit 38:288\u2013292","journal-title":"Ther Drug Monit"},{"key":"5974_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nep.12537","volume":"21","author":"J Wang","year":"2016","unstructured":"Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L (2016) Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology (Carlton) 21:21\u201327","journal-title":"Nephrology (Carlton)"},{"key":"5974_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00228-019-02781-3","volume":"76","author":"P Gao","year":"2020","unstructured":"Gao P, Guan X-L, Huang R, Shang-Guan X-F, Luan J-W, Liu M-C, Xu H, Wang X-W (2020) Risk factors and clinical characteristics of tacrolimus-induced acute nephrotoxicity in children with nephrotic syndrome: a retrospective case-control study. Eur J Clin Pharmacol 76:277\u2013284","journal-title":"Eur J Clin Pharmacol"},{"key":"5974_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12519-019-00257-z","volume":"16","author":"H-X Chen","year":"2020","unstructured":"Chen H-X, Cheng Q, Li F, He Q-N, Cao Y, Yi Z-W, Wu X-C (2020) Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome. World J Pediatr 16:159\u2013167","journal-title":"World J Pediatr"},{"key":"5974_CR57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/FTD.0000000000000955","volume":"44","author":"AM Rojas","year":"2022","unstructured":"Rojas AM, Hesselink DA, van Besouw NM, Dieterich M, de Kuiper R, Baan CC, van Gelder T (2022) High tacrolimus intrapatient variability and subtherapeutic immunosuppression are associated with adverse kidney transplant outcomes. Ther Drug Monit 44:369","journal-title":"Ther Drug Monit"},{"key":"5974_CR58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1034\/j.1399-3046.2002.02039.x","volume":"6","author":"G Filler","year":"2002","unstructured":"Filler G, Feber J, Lepage N, Weiler G, Mai I (2002) Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 6:411\u2013418","journal-title":"Pediatr Transplant"},{"key":"5974_CR59","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/j.1600-6143.2005.00844.x","volume":"5","author":"W Lemahieu","year":"2005","unstructured":"Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y (2005) Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 5:1383\u20131391","journal-title":"Am J Transplant"},{"key":"5974_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98:19\u201324","journal-title":"Clin Pharmacol Ther"},{"key":"5974_CR61","first-page":"721","volume":"87","author":"E Thervet","year":"2010","unstructured":"Thervet E, Loriot M, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P,\u00a0Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87:721\u2013726","journal-title":"Clin Pharmacol Ther"},{"key":"5974_CR62","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00431-021-04294-7","volume":"181","author":"T Nishimura","year":"2022","unstructured":"Nishimura T, Uemura O, Hibino S, Tanaka K, Kitagata R, Yuzawa S, Kasagi T, Fujita N (2022) Serum albumin level is associated with mycophenolic acid concentration in children with idiopathic nephrotic syndrome. Eur J Pediatr 181:1159\u20131165","journal-title":"Eur J Pediatr"},{"key":"5974_CR63","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","volume":"36","author":"BC de Winter","year":"2009","unstructured":"de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA (2009) Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmcodyn 36:541\u2013564","journal-title":"J Pharmacokinet Pharmcodyn"},{"key":"5974_CR64","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","volume":"77","author":"J Sobiak","year":"2015","unstructured":"Sobiak J, Resztak M, Ostalska-Nowicka D, Zachwieja J, G\u0105siorowska K, Piechanowska W, Chrzanowska M (2015) Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci 77:189\u2013196","journal-title":"Eur J Pharm Sci"},{"key":"5974_CR65","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1681\/ASN.V133759","volume":"13","author":"LT Weber","year":"2002","unstructured":"Weber LT, Shipkova M, Armstrong VW, Wagner N, Sch\u00fctz E, Mehls O, Zimmerhackl LB, Oellerich M, T\u00f6nshoff B (2002) The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759\u2013768","journal-title":"J Am Soc Nephrol"},{"key":"5974_CR66","doi-asserted-by":"publisher","unstructured":"Chan E, Yap D, Colucci M, Ma AL-t, Parekh R, Tullus K (2022) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533\u2013548. https:\/\/doi.org\/10.2215\/CJN.08570722","DOI":"10.2215\/CJN.08570722"},{"key":"5974_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.725665","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Shen Q, Dong M, Xiong Y, Xu H, Li Z (2021) Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome. Front Pharmacol 12:725665","journal-title":"Front Pharmacol"},{"key":"5974_CR68","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00467-021-05069-w","volume":"37","author":"Q Bertrand","year":"2022","unstructured":"Bertrand Q, Mignot S, Kwon T, Couderc A, Maisin A, Cambier A, Baudouin V, Peyneau M, Desch\u00eanes G, Hogan J (2022) Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. Pediatr Nephrol 37:357\u2013365","journal-title":"Pediatr Nephrol"},{"key":"5974_CR69","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/bjh.12434","volume":"162","author":"MJ Barth","year":"2013","unstructured":"Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L (2013) Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma\/leukaemia: a children\u2019s oncology group report. Br J Haematol 162:678\u2013683","journal-title":"Br J Haematol"},{"key":"5974_CR70","doi-asserted-by":"publisher","first-page":"1372859","DOI":"10.1155\/2017\/1372859","volume":"2017","author":"K Stahl","year":"2017","unstructured":"Stahl K, Duong M, Schwarz A, Wagner A, Haller H, Schiffer M, Jacobs R (2017) Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. Case Rep Nephrol 2017:1372859. https:\/\/doi.org\/10.1155\/2017\/1372859","journal-title":"Case Rep Nephrol"},{"key":"5974_CR71","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","volume":"37","author":"EY Chan","year":"2022","unstructured":"Chan EY, Ma AL, Tullus K (2022) Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37:927\u2013931. https:\/\/doi.org\/10.1007\/s00467-021-05345-9","journal-title":"Pediatr Nephrol"},{"key":"5974_CR72","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/FTD.0000000000000742","volume":"42","author":"G Filler","year":"2020","unstructured":"Filler G, Medeiros M, D\u00edaz-Gonz\u00e1lez de Ferris ME (2020) Appreciating the impact of tacrolimus sampling time deviations in pediatric patients with nephrotic syndrome. Ther Drug Monit 42:354\u2013356","journal-title":"Ther Drug Monit"},{"key":"5974_CR73","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/01.tp.0000231874.53240.ba","volume":"82","author":"S Satoh","year":"2006","unstructured":"Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K, Saito M, Inoue T, Miura M, Hayase Y (2006) Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 82:486\u2013493","journal-title":"Transplantation"},{"key":"5974_CR74","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2165\/00003088-200645080-00002","volume":"45","author":"M Baraldo","year":"2006","unstructured":"Baraldo M, Furlanut M (2006) Chronopharmacokinetics of ciclosporin and tacrolimus. Clin Pharmacokinet 45:775\u2013788","journal-title":"Clin Pharmacokinet"},{"key":"5974_CR75","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1097\/TP.0000000000002762","volume":"103","author":"DK Metz","year":"2014","unstructured":"Metz DK, Holford N, Kausman JY, Walker A, Cranswick N, Staatz CE, Barraclough KA, Ierino F (2014) Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention. Transplantation 103:2012\u20132030","journal-title":"Transplantation"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-05974-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-023-05974-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-05974-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:09:35Z","timestamp":1700827775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-023-05974-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5974"],"URL":"https:\/\/doi.org\/10.1007\/s00467-023-05974-2","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}